896 Shares in Axon Enterprise, Inc $AXON Bought by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. bought a new stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 896 shares of the biotechnology company’s stock, valued at approximately $502,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Axon Enterprise by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after buying an additional 53,060 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Axon Enterprise by 4.3% in the second quarter. BlackRock Inc. now owns 8,334,551 shares of the biotechnology company’s stock worth $4,672,432,000 after buying an additional 345,365 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Axon Enterprise by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock worth $1,265,657,000 after buying an additional 35,544 shares during the last quarter. Sands Capital Management LLC grew its holdings in Axon Enterprise by 11.6% during the fourth quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after acquiring an additional 167,095 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after acquiring an additional 1,179,038 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on AXON shares. The Goldman Sachs Group reiterated a “buy” rating and set a $715.00 price target on shares of Axon Enterprise in a research report on Thursday, August 6th. Needham & Company LLC restated a “buy” rating on shares of Axon Enterprise in a research report on Thursday, August 6th. Piper Sandler raised their price objective on shares of Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley lifted their target price on shares of Axon Enterprise from $600.00 to $640.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Thirteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $730.92.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $597.59 on Tuesday. The stock has a market capitalization of $48.55 billion, a price-to-earnings ratio of 247.96, a PEG ratio of 10.19 and a beta of 1.39. The stock has a 50-day moving average of $546.20 and a 200 day moving average of $478.02. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $794.29.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. The company had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.Axon Enterprise’s quarterly revenue was up 35.3% compared to the same quarter last year. During the same period last year, the company earned $2.12 earnings per share. Sell-side analysts anticipate that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Insider Activity

In related news, CRO Cameron Brooks sold 1,242 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the sale, the executive owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Patrick W. Smith sold 20,000 shares of Axon Enterprise stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $500.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the chief executive officer directly owned 3,060,997 shares in the company, valued at $1,530,498,500. This represents a 0.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 76,594 shares of company stock worth $41,236,386. Insiders own 4.20% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.